Supporting Innovation and Entrepreneurship for more than 60 years

Welcome to Safeguard Scientifics' Blog, where we share Perspective, Strategy and Insight.

Archive: John E. Shave

A Look Ahead

The Role of the Board in the IPO Process

Recently IPO or looking to go public in the next 12-18 months? Then you don’t want to miss the Pre- and Post-IPO Board Forum, hosted by NYSE Governance Services, Corporate Board Member, on Wednesday, December 11, 2013 at the offices of PwC, 3 Embarcadero Center, San Francisco, CA. This Board Forum is targeting newly listed public companies, as well as companies…

Read more

Investor Relations

RECAP: Safeguard Scientifics Third Quarter 2013 Financial Results

Safeguard announced third quarter 2013 financial results and reiterated increased aggregate partner company revenue guidance for 2013 to a range of $285 million to $295 million, up from initial revenue guidance of $250 million to $270 million. This represents an increase of 44% to 49% as compared to $197.3 million in 2012. We are enthusiastic about the performance of our partner companies during a time…

Read more

Corporate

Safeguard Increases Aggregate Partner Company Revenue Guidance for 2013

Safeguard announced that it has increased 2013 aggregate partner company revenue guidance to a range of $285 million to $295 million, up from its initial revenue guidance of $250 million to $270 million. This represents an increase of 44% to 49% as compared to $197.3 million in 2012. Results for Safeguard partner companies are reported on a one-quarter lag basis.…

Read more

Corporate

Safeguard Announces Final Agenda and Webcast for Investor Day 2013

Safeguard announced the final agenda and webcast information for Investor Day 2013. The event will be held at the New York Stock Exchange tomorrow, October 8, 2013 from 8:00 a.m. to 11:45 a.m. EDT.   AGENDA 8:00 a.m. — Registration and Breakfast 8:30 a.m. — Opening Remarks Stephen T. Zarrilli, President and CEO, Safeguard 8:45 a.m. — Specialty Pharmaceuticals Putney,…

Read more

Investor Relations

RECAP: Safeguard Scientifics Second Quarter 2013 Financial Results

Safeguard’s partner companies remain on track to achieve growth and operating, financial and strategic milestones. As a result, Safeguard reiterated aggregate partner company revenue guidance for 2013 to be between $250 million and $270 million. Although the M&A market remains a little spotty, by focusing on Safeguard’s core business in the near-term, we are confident that we can achieve strategic…

Read more